MedTrace Logo

A Phase I Study of BR108 in Hematological Malignancies

NCT06018506 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-11-21

No results posted yet for this study

Summary

A Phase I study of BR108 in hematological malignancies

Conditions

  • Hematologic Malignancy

Interventions

DRUG

BR108 injection

Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Sponsors & Collaborators

  • BioRay Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-18
Primary Completion
2024-05-27
Completion
2024-06-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018506 on ClinicalTrials.gov